Trade Ideas Based on Artificial Intelligence: Returns up to 24.91% in 7 Days

Trade Ideas

The Fundamental Package includes our algorithmic forecasts for stocks screened by fundamental criteria. Our algorithms help you find best opportunities for both long and short positions for the stocks within each fundamental screen. The trade ideas are selected according to five basic valuation categories:

    • P/E (price to earnings ratio)
    • PEG (price/earnings to growth ratio)
    • price-to-book ratio
    • price-to-sales ratio
    • short ratio

fundamentals
Package Name: Fundamental – Low P/E Stocks
Recommended Positions: Long
Forecast Length: 7 Days (06/28/2019 – 07/06/2019)
I Know First Average: 5.52%
Trade Ideas

I Know First’s State of the Art Algorithm accurately forecasted 7 out of 10 trades in this Fundamental – Low P/E Stocks Package for the 7 Days time period. The greatest return came from NERV at 24.91%. SPWR and OSTK also performed well for this time horizon with returns of 13.76% and 13.06%, respectively. The package itself saw an overall return of 5.52%, providing investors with a 3.28% premium above the S&P 500’s return of 2.24% for the same time period.

Minerva Neurosciences, Inc., incorporated on April 23, 2007, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202 (also known as JNJ-42847922), for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson’s disease.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.